MG
TXMD icon

Michael Gelband’s TherapeuticsMD TXMD Stock Holding History

Michael Gelband’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-751
Closed -$45K – 2646
2021
Q2 		$45K Sell
751
-686
-48% -$41.6K ﹤0.01% 2229
2021
Q1 		$96K Buy
+1,437
New +$112K ﹤0.01% 1983
2020
Q4 		– Sell
-298
Closed -$24K – 2385
2020
Q3 		$24K Sell
298
-801
-73% -$63.8K ﹤0.01% 1664
2020
Q2 		$69K Buy
+1,099
New +$64K ﹤0.01% 1662

Other funds holding TXMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Michael Gelband's TXMD Position: Q3 2021 in Review

Michael Gelband sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 751 shares — an estimated $45K sold.

Michael Gelband first reported a position in TXMD in Q2 2020 and held it in 4 quarters. The position peaked at $96K in Q1 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Michael Gelband reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 751 TherapeuticsMD shares in Q3 2021, an estimated $45K.
  • Michael Gelband first reported a position in TherapeuticsMD in Q2 2020 and held it in 4 quarters.
  • Michael Gelband's TherapeuticsMD position peaked at $96K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.